Due to the ever-increasing instances of chronic obstructive pulmonary disease (COPD) across the globe, offering promising healthcare solutions at a reduced price has become an indispensable task for COPD drugs manufacturers. Moreover, leading firms operating in the COPD drugs manufacturing space are forced to provide more dynamic and robust product offerings. As a result, leading COPD drugs manufacturers have started leveraging the use of cost benefit analysis. Additionally, cost benefit analysis help firms operating in the COPD drugs manufacturing space to meet the rising demand of the customers and reduce expenditures across the supply chain.
With years of experience in offering a wide array of similar solutions, SpendEdge’s cost benefit analysis experts help firm operating in the COPD drugs manufacturing space to gain a complete understanding of the cost structure for their supply chain activities. These solutions also help clients achieve a competitive edge over the peers by formulating superior negotiation strategies with suppliers in the industry space.
The Procurement Pain Point and Insights Offered
A leading COPD drugs manufacturing client was facing predicaments in devising a low-cost mix model to cut down the overall sourcing and procurement costs across the supply chain. Moreover, the client wanted to gain actionable insights into the negotiation levers adopted by suppliers. Also, the client wanted to identify cost elements and assess its impact on the overall cost.
To cater to the specific predicaments faced by the COPD drugs manufacturing client and help them assess the cost structure across the supply chain, the cost benefit analysis experts at SpendEdge tailored an integrated research methodology, which included primary and secondary research coupled with quantitative and qualitative data collection methodologies.
During the course of the cost benefit analysis engagement, the COPD drugs manufacturing client was able to gauge the impact of individually cost driver on the overall spends and forecast the cost movements across the supply chain. Additionally, the client was able to devise low-cost mix model which helped them cut down the overall sourcing and procurement cost.
Vital questions answered in this cost benefit analysis study include
The cost benefit analysis engagement helped the COPD drugs manufacturing client gain profound and actionable insights into the cost structure of their sourcing and procurement processes. This enabled them to devise superior negotiation strategies with their suppliers and consequently reduced the overall costs.